Sylvester Stallone TRT: The Evidence Base Behind That Protocol

What Stallone Has Actually Said About TRT

Stallone has not hidden his hormone use. He is one of the few public figures who named specific compounds, doses, and rationale in mainstream media.

In a 2008 interview with Time magazine, Stallone stated: "Everyone over 40 years old would be wise to investigate it because it increases the quality of your life. Mark my words. In 10 years it will be over the counter." He was referring primarily to human growth hormone and testosterone. He described taking HGH at 2 IU daily at that time and testosterone at a self-reported dose consistent with replacement ranges. That statement predates the current wave of celebrity TRT discourse by nearly 15 years.

The 2007 Australia Incident

In February 2007, Australian customs officials seized 48 vials of Jintropin (somatropin, a recombinant human growth hormone product) from Stallone at Sydney Airport. He pleaded guilty in a Sydney court and was fined AUD 10,000. Jintropin is a brand of somatropin manufactured by GeneScience Pharmaceuticals. In Australia, importing HGH without a valid prescription is a criminal offense under the Therapeutic Goods Act 1989.

This event confirmed that Stallone was sourcing pharmaceutical-grade peptide hormones in quantities well above what an individual could use in a short visit.

Ongoing Public Statements

Beyond 2008, Stallone referenced TRT and hormonal optimization in interviews with outlets including Men's Health and on social media. He framed the therapy as preventive medicine rather than performance enhancement. None of these statements have been clinical disclosures with labs attached, so exact serum testosterone levels and specific TRT formulations in current use are not publicly documented. Where this article discusses his likely protocol, that is clearly labeled as inference from standard clinical practice.

How TRT Is Diagnosed and Prescribed: The Guideline Framework

A celebrity's public statements carry no clinical weight unless the underlying science supports the practice. For testosterone replacement therapy, that science is substantial.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy defines hypogonadism as "a clinical syndrome that results from failure of the testis to produce physiological concentrations of testosterone." [1] Diagnosis requires two separate morning serum total testosterone measurements below 300 ng/dL combined with signs or symptoms: reduced libido, erectile dysfunction, decreased energy, loss of muscle mass, increased adiposity, or depressed mood.

Biochemical Thresholds

The 300 ng/dL cutoff is not arbitrary. Data from the European Male Ageing Study (N=3,369) showed that men with total testosterone below 317 ng/dL were significantly more likely to report three or more sexual symptoms compared with eugonadal men [2]. The same dataset informed the Endocrine Society's decision to place the lower limit of normal at approximately 300 to 350 ng/dL.

Free testosterone matters too, particularly in older men whose sex hormone-binding globulin (SHBG) rises with age. The Endocrine Society guideline recommends measuring free testosterone when total testosterone is borderline (300 to 400 ng/dL) [1]. A calculated free testosterone below 65 pg/mL may support a diagnosis even when total testosterone is in the low-normal range.

Age-Related Decline

Serum testosterone declines at roughly 1 to 2% per year after age 30 [3]. By their 50s, a meaningful fraction of men fall below diagnostic thresholds. Data from the Baltimore Longitudinal Study of Aging confirmed progressive decline in both total and free testosterone across decades [3]. For a man born in 1946 who was in his late 50s during his public disclosures, the physiological case for low testosterone is biologically plausible, though individual labs are not available.

Testosterone Formulations: What a Protocol Like Stallone's Likely Involves

Stallone has not published a prescription record. Inference here is based on the formulations most commonly prescribed for men in his age group and activity level during the period he was most vocal about TRT (roughly 2005 to 2015).

Testosterone Cypionate and Enanthate

These are long-acting injectable testosterone esters. Testosterone cypionate 200 mg IM every 14 days (or 100 mg every 7 days for smoother serum levels) remains one of the most commonly prescribed TRT formulations in the United States [4]. Peak serum testosterone after a 200 mg injection occurs at roughly 24 to 48 hours and falls to near-baseline by day 14, which is why weekly dosing is now preferred by most endocrinologists.

The FDA approved testosterone cypionate (Depo-Testosterone, Pfizer) for hypogonadism treatment; the full prescribing information is publicly available [4].

Transdermal Options

Testosterone 1.62% gel (AndroGel, AbbVie) produces steady-state serum testosterone within 24 to 48 hours of daily application and avoids the peak-trough fluctuation of injections [5]. In the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men 65 and older with low testosterone, transdermal testosterone gel was the delivery method used [6]. The TTrials enrolled 790 men and showed improved sexual function, mood, and walking distance at 12 months [6].

Subcutaneous Pellets

Testosterone pellets (Testopel) implanted subcutaneously every 3 to 6 months provide sustained release. They are used less often than injectables or gels but are FDA-approved. Stallone's travel schedule and filming commitments make pellets or long-acting injectables plausible choices, though this is inference.

The Cardiovascular Evidence: TRAVERSE and What It Settled

For years, the single largest concern about TRT was cardiovascular risk. A 2010 Basaria et al. Trial in the NEJM (N=209, men aged 65+ with mobility limitations) was halted early after a higher rate of cardiovascular events appeared in the testosterone arm [7]. That finding caused significant regulatory alarm and led to an FDA label change in 2015 requiring cardiovascular risk disclosure on all testosterone products.

TRAVERSE (Testosterone Replacement in Men with Hypogonadism and Either Low Cardiovascular Risk or Established Cardiovascular Disease) addressed this directly. The trial enrolled 5,246 men aged 45 to 80 with confirmed hypogonadism (total testosterone 100 to 300 ng/dL) and either established or high risk for cardiovascular disease. Participants received daily testosterone gel 1.62% or placebo for a median of 33 months [8].

The primary endpoint, major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), occurred in 7.0% of testosterone recipients and 7.3% of placebo recipients. Hazard ratio 0.96 (95% CI 0.78 to 1.17), confirming non-inferiority [8]. TRAVERSE was published in the New England Journal of Medicine in 2023 and is now the most definitive cardiovascular safety dataset for TRT.

The FDA reviewed TRAVERSE data and updated the testosterone prescribing label in 2023 to reflect the non-inferiority finding [4].

What TRAVERSE Did Not Resolve

TRAVERSE also found a higher rate of atrial fibrillation in the testosterone arm (3.5% vs. 2.4%, P<0.001) and a higher rate of acute kidney injury (2.3% vs. 1.5%) [8]. These signals are modest but real. Men with pre-existing atrial fibrillation or impaired renal function should have those conditions factored into the treatment decision.

Pulmonary embolism rate was numerically higher in the testosterone group as well (0.9% vs. 0.5%), consistent with the known polycythemia risk. Testosterone stimulates erythropoiesis; hematocrit above 54% is a standard stopping criterion [1].

HGH: The Other Half of the Stallone Protocol

Human growth hormone is the compound that actually landed Stallone in court in 2007. The clinical picture here is different from TRT.

What GH Does in Adults

Recombinant human growth hormone (somatropin) is FDA-approved for adult growth hormone deficiency (AGHD), a condition diagnosed by provocative GH stimulation testing showing a peak GH below 5 ng/mL [9]. Symptoms of AGHD include increased visceral adiposity, reduced lean mass, fatigue, and impaired quality of life, features that overlap substantially with normal aging.

The FDA has not approved somatropin for anti-aging, body composition enhancement in healthy adults, or athletic recovery [9]. Prescribing it for those indications is considered off-label, and distributing or importing it for those purposes is illegal in the United States and Australia.

Evidence for Body Composition Effects

In a meta-analysis of 31 randomized controlled trials (N=1,014), Liu et al. (Annals of Internal Medicine, 2007) found that GH supplementation in healthy older adults reduced fat mass by 2.1 kg and increased lean mass by 2.1 kg, but did not improve functional outcomes including exercise capacity or quality-of-life scores [10]. The Annals editorial accompanying that meta-analysis stated: "The harms from growth hormone supplementation outweigh the benefits in healthy older adults, given the increased risk of soft tissue edema, arthralgias, carpal tunnel syndrome, and possible promotion of occult malignancy."

Adverse events in the Liu meta-analysis included edema in 39.7% of GH recipients, arthralgias in 24.5%, carpal tunnel syndrome in 17.2%, and gynecomastia in 4.9% [10].

GH and IGF-1 Cancer Risk

IGF-1, the primary mediator of GH anabolic effects, is a mitogen. Elevated IGF-1 has been associated with increased risk of colorectal, prostate, and premenopausal breast cancer in large prospective cohorts [11]. The association does not establish causation, and the absolute risk magnitudes are small, but oncologists consistently list this concern when patients ask about GH supplementation for non-approved purposes.

How TRT Affects Muscle Mass and Body Composition

Stallone's physique at 70+ is the context most people bring to this question. What does the evidence actually say about TRT and body composition in older men?

Lean Mass

The Testosterone Trials (TTrials, N=790, men 65+, mean baseline testosterone 232 ng/mL) showed that testosterone gel significantly increased lean mass by 1.6 kg and reduced fat mass by 1.2 kg at 12 months vs. Placebo [6]. These are statistically significant but modest changes. They do not explain the degree of muscle development visible in Stallone's public appearances, which reflects decades of resistance training, high protein intake, and (by his own admission) other hormonal support.

Strength

A 2018 Cochrane systematic review of testosterone therapy in men over 45 (34 RCTs, N=2,038) found a weighted mean difference in grip strength of 2.1 kg vs. Placebo, with moderate heterogeneity across trials [12]. Functional strength improvements were more consistent in men with baseline testosterone below 250 ng/dL.

The Training Factor

Resistance training is a far larger driver of muscle hypertrophy than TRT alone. A 2001 Bhasin et al. Study in the NEJM (N=61, healthy men aged 19 to 40) showed that testosterone enanthate 600 mg per week (a supraphysiologic dose, three to six times a standard TRT dose) combined with resistance training increased fat-free mass by 6.1 kg at 10 weeks vs. 1.9 kg for training alone and 3.2 kg for testosterone alone without training [13]. Even at supraphysiologic doses, training was additive.

Monitoring a TRT Protocol: What Clinical Guidelines Require

The Endocrine Society guideline specifies monitoring at 3 months after initiation, then annually [1]. Required labs include:

• Serum total testosterone (target 400 to 700 ng/dL mid-cycle for injectables)
• Hematocrit (stop or reduce dose if above 54%)
• PSA (baseline and 3 to 6 months; consider urology referral if PSA rises more than 1.4 ng/mL in 12 months)
• Digital rectal exam at baseline in men over 40
• Bone mineral density at baseline if osteoporosis is a concern

The guideline states: "We recommend against starting testosterone therapy in patients who are actively trying to father a child" because exogenous testosterone suppresses LH and FSH, shutting down spermatogenesis [1]. For men on TRT who want to preserve fertility, hCG co-administration at 500 IU subcutaneously every other day maintains intratesticular testosterone.

Polycythemia: The Most Common TRT Side Effect in Older Men

Hematocrit elevation is the most frequently encountered adverse effect in men over 60 on TRT. Testosterone stimulates erythropoietin production in the kidney, raising red blood cell mass. In the TTrials, hematocrit exceeded 54% in 7.5% of testosterone recipients vs. 1.5% of placebo recipients at 12 months [6].

Polycythemia raises blood viscosity and theoretical thrombosis risk. The Endocrine Society recommends dose reduction or temporary discontinuation if hematocrit rises above 54%, followed by re-checking in 3 to 4 weeks before resuming therapy [1]. Phlebotomy is an option in men with persistent elevation who want to continue TRT.

What "Testosterone Optimization" Clinics Offer vs. Guideline-Based Care

A distinction worth making: guideline-based TRT targets serum testosterone in the mid-normal range (roughly 400 to 700 ng/dL). A number of direct-to-consumer testosterone clinics, sometimes called "men's health" or "optimization" clinics, target higher serum levels (700 to 1,100 ng/dL) and may co-prescribe anastrozole (an aromatase inhibitor to suppress estradiol), hCG (to maintain testicular size and intratesticular testosterone), and sometimes DHEA.

None of these combination protocols have been studied in the long-term RCTs that exist for standard-dose TRT. The TRAVERSE trial used standard replacement doses, not optimization doses. Extrapolating TRAVERSE's cardiovascular safety data to higher-dose protocols is not supported by the evidence.

The FDA has approved testosterone for documented hypogonadism, not for raising levels in eugonadal men. Prescribing TRT to a man with a normal testosterone level is off-label.